首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

2126642

視網膜藥物市場：依藥物類別、適應症、給藥途徑及地區分類。

Retinal Drugs Market, By Drug Class, By Indication, By Route of Administration, By Geography

出版日期: 2026年08月28日 | 出版商:

Coherent Market Insights | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，視網膜藥物市場規模將達到 241.8 億美元，到 2033 年將達到 411.7 億美元。預計 2026 年至 2033 年的複合年成長率將達到 7.9%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	241.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.90%	2033年市場規模預測：	411.7億美元

全球視網膜治療市場是眼科和製藥行業中一個快速成長的領域，涵蓋了多種主要視網膜疾病的治療，例如老齡化黃斑部病變（AMD）、糖尿病視網膜病變、視網膜靜脈阻塞和遺傳性視網膜疾病。該市場包括抗VEGF藥物、皮質類固醇、補體抑制劑以及針對各種視網膜疾病機制的新興基因療法。

全球人口老化、糖尿病盛行率上升以及威脅視力的視網膜疾病負擔日益加重，正在推動市場成長。同時，緩釋藥物傳遞系統、生物相似藥、基因療法和精準療法的進步，正在拓展治療選擇，並改變視網膜疾病的治療方式。

市場動態

全球視網膜治療市場主要受視網膜疾病發生率上升（尤其是老齡化黃斑部病變(AMD) 和糖尿病視網膜病變）以及對有效視力治療需求不斷成長的推動。抗 VEGF 療法繼續佔據市場主導地位，對新型長效製劑和視網膜基因療法的投入增加推動了市場成長，同時視網膜醫療基礎設施的改善也擴大了治療的可及性。

然而，視網膜藥物市場的成長受到許多因素的限制，例如治療費用高昂、醫保報銷有限以及玻璃體內注射帶來的操作負擔。儘管如此，專利到期為生物相似藥的開發帶來了機遇，而緩釋植入植入、新型給藥系統和基因療法的進步也為創新開闢了新的途徑。亞太、拉丁美洲以及中東和非洲等新興市場也蘊藏著巨大的成長潛力。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球視網膜藥物市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使行銷負責人和企業經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份「全球視網膜治療市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用全球視網膜治療市場分析中採用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

公司簡介
- Regeneron Pharmaceuticals, Inc.
- Hoffmann-La Roche Ltd
- Novartis AG
- AbbVie Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Amgen Inc.
- Santen Pharmaceutical Co., Ltd.
- Bausch+Lomb Corporation
- Astellas Pharma Inc.

第9章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI10012

Retinal Drugs Market is estimated to be valued at USD 24.18 Bn in 2026 and is expected to reach USD 41.17 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 24.18 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.90%	2033 Value Projection:	USD 41.17 Bn

The global retinal drugs market is a fast-growing segment of the ophthalmology and pharmaceutical industries, covering therapies for major retinal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and inherited retinal diseases. The market comprises anti-VEGF agents, corticosteroids, complement inhibitors, and emerging gene-based therapies that target various retinal disease mechanisms.

Increasing aging population worldwide, increasing prevalence of diabetes, and increasing burden of vision-threatening retinal disorders are aiding the market growth. Meanwhile, advancements in sustained drug-delivery systems, biosimilars, gene therapies, and precision treatment approaches are expanding the therapeutic options and reshaping the retinal disease treatment landscape.

Market Dynamics

The global retinal drugs market is driven by rising incidence of retinal diseases, especially age-related macular degeneration (AMD) and diabetic retinopathy, and increasing demand for effective treatments to preserve vision. The anti-VEGF treatment continues to dominate the market, with new longer-acting formulations and increased funding for retinal gene therapies driving market growth, while improved retinal-care infrastructure is expanding treatment availability.

However, the growth of retinal drugs market is limited by factors such as high treatment costs, reimbursement limitations and procedural burden of intravitreal administration. Nevertheless, patent expiries are opening up opportunities for biosimilars, while advances in sustained-release implants, novel delivery systems and gene therapies are providing new avenues for innovation, emerging markets across Asia Pacific, Latin America and Middle East & Africa also offer significant growth potential.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global retinal drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Amgen Inc., Santen Pharmaceutical Co., Ltd., Bausch + Lomb Corporation, and Astellas Pharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global retinal drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global retinal drugs market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
Anti-VEGF Agents
Corticosteroids
Complement Inhibitors
Others
Indication Insights (Revenue, USD Bn, 2021 - 2033)
Age-Related Macular Degeneration (AMD)
Diabetic Retinopathy / Diabetic Macular Edema (DME)
Retinal Vein Occlusion (RVO)
Inherited Retinal Diseases
Others
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Intravitreal
Subretinal
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc.
Bayer AG
Apellis Pharmaceuticals, Inc.
Amgen Inc.
Santen Pharmaceutical Co., Ltd.
Bausch + Lomb Corporation
Astellas Pharma Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Retinal Drugs Market, By Drug Class
- Global Retinal Drugs Market, By Indication
- Global Retinal Drugs Market, By Route of Administration
- Global Retinal Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. Global Retinal Drugs Market, By Drug Class, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Anti-VEGF Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Complement Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Retinal Drugs Market, By Indication, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Age-Related Macular Degeneration (AMD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Diabetic Retinopathy / Diabetic Macular Edema (DME)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retinal Vein Occlusion (RVO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Inherited Retinal Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Retinal Drugs Market, By Route of Administration, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Intravitreal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Subretinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Retinal Drugs Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Company Profile
- Regeneron Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Apellis Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Santen Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bausch + Lomb Corporation
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Astellas Pharma Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies